| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $64K | -87.2% |
| Cost of Revenue | $6.7M | +29.5% |
| Gross Profit | -$6.6M | -42.1% |
| R&D Expense | $1.5M | -79.9% |
| SG&A Expense | $8.6M | -39.9% |
| Operating Income | -$19.4M | +31.2% |
| Pre-tax Income | -$1.8M | +94.9% |
| Net Income | -$1.8M | +94.9% |
| EPS (Basic) | -$2.02 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $16.0M | -52.0% |
| Short-term Investments | $4.1M | — |
| Accounts Receivable | $219K | +0.0% |
| Inventory | $3.4M | +0.0% |
| Current Assets | $21.3M | -56.6% |
| Total Assets | $21.7M | -58.9% |
| Current Liabilities | $4.2M | -3.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$13.3M | +49.1% |
| Capital Expenditures | $199K | -90.7% |
| Investing Cash Flow | -$3.1M | -134.5% |
| Financing Cash Flow | -$10.9M | -150.2% |
| Free Cash Flow | -$13.5M | +52.3% |
| +75.3% |
| EPS (Diluted) | -$2.02 | +75.3% |
| Total Liabilities |
| $9.5M |
| -65.6% |
| Stockholders' Equity | $4.7M | -66.9% |